Human telomerase reverse transcriptase (hTERT) is expressed in most cancer cells. Paradoxically, its promoter is embedded in a hypermethylated CpG island. A short region escapes to this alteration, allowing a basal level of transcription. However, the methylation of adjacent regions may play a role in the maintenance of low hTERT expression. It is now well established that methyl-CpG binding domain proteins mediate the transcriptional silencing of hypermethylated genes. The potential involvement of these proteins in the control of hTERT expression was firstly investigated in HeLa cells. Chromatin immunoprecipitation assays showed that only methyl-CpG-binding domain protein 2 (MBD2) associated the hypermethylated hTERT promoter. In MBD2 knockdown HeLa cells, constitutively depleted in MBD2, neither methyl CpG binding protein 2 (MeCP2) nor MBD1 acted as substitutes for MBD2. MBD2 depletion by transient or constitutive RNA interference led to an upregulation of hTERT transcription that can be downregulated by expressing mouse Mbd2 protein. Our results indicate that MBD2 is specifically and directly involved in the transcriptional repression of hTERT in HeLa cells. This specific transcriptional repression was also observed in breast, liver and neuroblastoma cancer cell lines. Thus, MBD2 seems to be a general repressor of hTERT in hTERT-methylated telomerase-positive cells.
Introduction
An increasing body of evidences indicate that the alterations of DNA methylation patterns are a characteristic of cancer cells (1) . Generally, global reduction of DNA methylation level is associated with localized hypermethylation (1) . Specifically, an aberrant hypermethylation of CpG islands at the 5# end of tumor suppressor genes, leading to transcriptional repression, has been described both in cancer cell lines and tumor tissues (2, 3) .
In human epithelial and fibroblast cells, telomere shortening is a key event in replicative senescence. In .85% of cancer cells, telomere length is maintained through telomerase holoenzyme activity (4, 5) . Although germ cells and stem cells also exhibit high telomerase activity (4) , in normal somatic cells, the catalytic subunit of the telomerase [human telomerase reverse transcriptase (hTERT)] is silenced, leading to a limited life span (6) . The regulation of hTERT transcription has been extensively investigated and several inductors and repressors have been identified, including c-Myc, Sp1, hALP, Hif-1, Mbi-1, USF1/2, estrogen response element, p53, Mad1, myeloidspecific zinc finger protein 2, transforming growth factor-b, Wilms' Tumor 1 and CTCF (7) (8) (9) . In addition, the hTERT promoter region is embedded in a large CpG island spanning nucleotides (nt) À1100 to þ1500 from the transcription start site, suggesting that transcription of the gene might be regulated by DNA methylation.
The first studies examining the methylation status of the hTERT CpG island had led to a paradox. In normal somatic cells, this CpG island was found unmethylated while the gene was transcriptionally silent. However, in most of cancer cells, this region was aberrantly methylated, whereas telomerase activities and hTERT messenger RNAs (mRNAs) were unambiguously detected (10) (11) (12) (13) . This paradox was recently solved. hTERT methylation prevents the binding of negatively acting transcription factors such as CTCF inhibitor (9) , and a partial hypomethylation of the hTERT promoter region can result in some level of transcriptional activity (14) . In several cancer cell lines and tumor tissues, careful analysis of hTERT methylation patterns has shown that a short region of the CpG island (positions nt À165 to nt À80) is unmethylated or slightly methylated despite highly methylated border regions (14) . This unmethylated region is located in the hTERT core promoter (positions nt À279 to nt þ5) (15) , and chromatin immunoprecipitation (ChIP) assays have shown that active chromatin marks are associated with this unmethylated region (16) . Moreover, studies using plasmid expression vectors and patch methylation techniques indicate that the hTERT core promoter does not show any activity when all CpG sites are methylated (17) . In contrast, the selective demethylation of a small region upstream the transcription start site significantly activates the hTERT promoter in a reporter plasmid. Nevertheless, the activity of the promoter under these conditions is significantly lower than when using the unmethylated core promoter. In this condition, hTERT does not provide a real exception to the general model of gene silencing by promoter methylation and the hypermethylation around the unmethylated region seems to play a major role in the reduction of hTERT transcriptional activity. Indeed, in telomerase-positive cancer cells, only 0.2-6 mRNA molecules per cell can be detected (18, 19) , suggesting that the transcriptional activity of the hTERT promoter is limited by cellular factors since high transcription rates are induced when the unmethylated promoter is used in plasmid expression vectors (14) .
Transcriptional repression mediated by CpG methylation often involves methyl-CpG-binding domain (MBD) proteins. The five MBD proteins identified to date, methyl CpG binding protein 2 (MeCP2), MBD1, MBD2, MBD3 and MBD4, share a highly conserved MBD. With the exception of MBD4, which is primarily a thymine glycosylase involved in DNA repair (20) , all MBD proteins are involved in the transcriptional repression mediated by DNA methylation. It has now been well established that MeCP2, MBD1 and MBD2 bind to methylated DNA and recruit different histone deacetylase complexes and histone methyl transferases, belonging to the chromatin remodeling complexes that control chromatin compaction and induce gene silencing (21) (22) (23) . MBD3 lacks a functional MBD but is an integral subunit of histone deacetylase complex the Mi2-NuRD complex that is recruited through MBD2 (24, 25) .
These data have prompted us to investigate whether MBD proteins are involved in the repression of hTERT expression when hypermethylated in telomerase-positive cells.
Materials and methods

Cell culture
Five human tumor cell lines, HeLa (cervical adenocarcinoma), MCF7 (breast adenocarcinoma), HepG2 (hepatocellular carcinoma), LAN-1 (neuroblastoma) and NCCIT (teratocarcinoma) and a normal human embryonic lung fibroblast cell line, MRC5, were used in this study. Cells were obtained from the American Type Culture Collection (Rockville, MD), except for LAN-1, and grown in the medium recommended at 37°C in a humidified 5% CO 2 atmosphere.
ChIP assays
ChIP was done as described previously (26) . Cross-linked chromatin was immunoprecipitated using 15 ll of two different polyclonal anti-MBD2 antibodies (kindly provided by Dr P.Wade and Dr E.Ballestar) or 20 ll of polyclonal antiMeCP2 (Upstate Biotechnology, Lake Placid, NY), anti-MBD1 (Abcam, Paris, France) antibodies or anti-mouse IgG (Dakocytomation, Trappes, France).
Purified DNAs obtained from the input, unbound and bound fractions were quantified by densitometry using the VersaFluor TM Fluorometer (Bio-rad, Ivry, France) and RiboGreen reagent (Molecular Probes, Interchim, Montluc xon, France).
Polymerase chain reaction (PCR) analysis was then performed to assess the binding of MBD proteins to the hTERT core promoter. An equal quantity (0.4 ng) of each DNA fraction was amplified by dose-dependent PCR (supplementary Figure S1 is available at Carcinogenesis Online) using HotStar Taq polymerase Kit (Qiagen, Courtaboeuf, France), 5% of dimethyl sulfoxide and 0.5 lM of primers spanning a region from nt À296 to nt À84 of hTERT (hTERT ChIP, see supplementary Table S1 available at Carcinogenesis Online). The thermal cycler program was 37 cycles of 94°C for 30 s, 65°C for 60 s and 72°C for 90s. PCR products were analyzed on a 2% agarose gel containing 1 lg/ml ethidium bromide and were quantified by densitometry using a Fluor's fluorimeter and Quantity One software (Bio-rad).
ChIP-on-chip
For ChIP-on-chip analysis, the specific protein-DNA complexes were obtained from independent immunoprecipitations using two different polyclonal anti-MBD2 antibodies (kindly provided by Dr P.Wade and Dr E.Ballestar). The ChIP DNAs from the input and bound fractions were amplified, labeled and hybridized on microarrays by ProfileXpert service according to Affymetrix TM protocols. Briefly, the ChIP DNA was amplified by ligation-mediated PCR. To test for enrichment of MBD2-bound sites, PCR amplification of NBR2 (26) and pS2 promoters was performed on each ChIP samples before and after amplification. The amplified DNAs were then labeled using the GeneChipÒ WT Double-Stranded DNA Terminal Labelling Kit and hybridized to the human tiling arrays (Human Promoter 1.0R Arrays), which were then washed and scanned. Raw data from the scans were analyzed using AffymetrixÒ Tiling Analysis Software and the results were viewed in Affymetrix' Integrated Genome Browser Software.
DNA methylation analysis
Bisulfite sequencing used to determine the CpG methylation pattern of hTERT promoter and proximal exonic region was performed as described previously (12, 14) . Briefly, bisulfite-modified genomic DNA was amplified by two primer sets [P1, positions nt À442 to nt À219 (12) and P2, positions nt À206 to nt þ108 (14) ] to analyze a region from nt À442 to nt þ108 from the transcription start site of hTERT. PCR amplifications were accomplished using the master mix (Promega, Madison, WI), with the following conditions: 40 cycles of 94°C for 30 s, 54°C (P1) or 57°C (P2) for 45 s and 72°C for 50 s. DNA methylation status was then established by a direct sequencing of PCR products or by a sequencing of cloned PCR products. For the last procedure, PCR products were cloned into the pGEM-T vector using the pGEM-T vector system II (Promega). After transformation of JM109 Escherichia coli competent cells (Promega), plasmid DNA was extracted from clones with the QIAprep Spin Miniprep Kit (Qiagen). Each clone was sequenced with the M13 forward primer (5#-GTAAAACGACGGCCAG-3#), using a Big Dye Terminator Cycle Sequencing Kit and an ABI Prism 3100 sequencer (Applied Biosystems, Foster City, CA).
Transient transfection siRNA duplexes for MBD2 (sense: 5#-GGAGGAAGUGUACCGAAAATT-3# and antisense: 5#-UUUUCGGAUCACUUCCUCCTT-3#; Eurogentec, Seraing, Belgium); non-specific small interfering RNA (siRNA) control (Eurogentec); pRev-Mbd2 (kindly provided by Dr A.Bird) (26) and pGL3 basic (Promega) were transfected in cell lines using lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the manufacturer's recommendations. Briefly, cells were seeded at 2 Â 10 5 cells per well in six-well plates and grown to 50-60% confluence on the day of transfection. All transfections were done in Opti-MEM medium (Invitrogen) with 625 nM of MBD2 siRNA or 1 lg of Mbd2 expression plasmid. Lipofectamine 2000 complexes were incubated for 4-5 h. The medium was then removed and replaced with fresh medium. Cells were grown and harvested at various time after the transfection.
RNA extraction and reverse transcription-PCR analysis
Total RNA was extracted from cells using the RNeasy Mini Kit (Qiagen). After extraction, the integrity of total RNA was examined on a 1.2% agarose gel containing 1 lg/ml ethidium bromide and quantified by densitometry using a Fluor's fluorimeter and Quantity One software (Bio-rad) by comparison with serial dilutions of a standard RNA (Roche Molecular Biochemicals, Maylan, France).
MBD2 mRNA was quantified by competitive quantitative reverse transcription (RT)-PCR as described previously (27) . hTERT mRNA levels were monitored by relative RT-PCR using One Step RT-PCR kit (Qiagen) and 0.1 lg of total RNA. Cycling parameters were 50°C for 30 min followed by 95°C for 15 min and then 32 cycles of 94°C for 30 s, 55°C for 60 s and 72°C for 90 s. hTERT transcripts were co-amplified with PBGD transcripts used as internal controls (for primers hTERT RT-PCR and PBGD RT-PCR, see supplementary Table S1 available at Carcinogenesis Online). PCR products were analyzed on a 2% agarose gel containing 1 lg/ml ethidium bromide and quantified by densitometry. The ratio between hTERT and PBGD signals was determined. To quantify more precisely hTERT mRNA, real-time RT-PCR was also carried out on a Rotorgene 6000 cycler (Corbett Research, Sydney, Australia) using C. therm. Polymerase One-Step RT-PCR System (Roche Molecular Biochemicals, Maylan, France). Each reaction mixture included 50 ng of template RNA, 250 nM of FAM-labeled probe (see supplementary Table S1 available at Carcinogenesis Online) and 500 nM of primers specific for hTERT (hTERT RT-PCR Q, see supplementary Table S1 available at Carcinogenesis Online). Cycling parameters were 60°C for 30 min followed by 95°C for 5 min and then 45 cycles at 95°C for 15 s and 60°C for 60 s. b-Actin mRNA levels were used to normalize hTERT expression. The relative level of each mRNA was calculated on the basis of two standard curves using the relative quantification method.
Results
hTERT hypermethylated CpG island is selectively associated with MBD2 in HeLa cells
To explore the potential involvement of MBD proteins in hTERT regulation, we have chosen cervical cancer cell line HeLa, as a first model. In these telomerase-positive tumor cells, as was shown in our earlier studies, the hTERT core promoter is also regionally hypermethylated (17) and might be a target of MBD proteins.
To address this issue, ChIP assays were performed using antibodies directed against MeCP2, MBD1 and MBD2. As a control, the fractions immunoprecipitated with a non-MBD protein-specific antibody (anti-mouse IgG) were also analyzed. The relative amounts of hTERT core promoter were determined by a dose-dependent PCR assay (supplementary Figure S1 available at Carcinogenesis Online) using a constant amount of DNA from each fractionation process: input, unbound and bound fractions. Representative data from at least three independent experiments are shown in Figure 1A . A strong enrichment in hTERT promoter was observed in the fraction immunoprecipitated by anti-MBD2 antibodies when compared with input or non-retained fractions ( Figure 1A 'input', 'unbound' and 'IgG'). Since dosedependent PCR assays were performed with a constant amount of DNA, these data strongly suggest that MBD2 is associated with the methylated region of the hTERT promoter. In contrast, analysis of the fractions immunoprecipitated by anti-MeCP2 or anti-MBD1 antibodies showed that these fractions were depleted in hTERT DNA ( Figure  1A ), indicating that these two proteins are not bound to hTERT promoter in HeLa cells. Furthermore, the depletion in hTERT DNA observed in the fractions bound by anti-MeCP2 and anti-MBD1 antibodies suggests that these two proteins are probably linked to other chromatin domains in HeLa cells.
Taken together, these data strongly suggest that the methylated regions adjacent to the unmethylated region of the hTERT core promoter are selectively associated with MBD2.
Recently, we have developed high-throughput analyses of MBD2-binding pattern using a ChIP-on-chip approach (A. Chatagnon, L. Perriaud, J. Lachuer and R. Dante, in preparation). DNAs obtained from the chromatin immunoprecipitated by anti-MBD2 antibodies were hybridized to Affymetrix Human Promoter 1.0R Array. On this chip, 25 500 human promoter regions tiled at 35 bp resolution are representing. Each promoter region covers $7.5 kb upstream through 2.45 kb downstream of 5# transcription start site and for 1300 cancerassociated genes, additional 2.45 kb are also represented. Data obtained from two independent experiments performed with two different anti-MBD2 antibodies indicated that MBD2 not only bound the MBD2 is a selective repressor of hTERT hypermethylated region of the hTERT core promoter but also covered all the hypermethylated hTERT CpG island ( Figure 2A) . As a control, results obtained for a previously identified MBD2-free hypermethylated promoter (28), PARVG, are also shown on Figure 2B . As expected, no MBD2-positive signal was observed along this hypermethylated promoter ( Figure 2B ).
The hypermethylated hTERT promoter remains free of MBD proteins in MBD2-depleted cells In HeLa cells, among the MBD transcripts, MBD2 mRNAs are the most abundant (27) , suggesting that the selective binding of MBD2 to hTERT promoter might be due to its prominent expression. Thus, we investigated hTERT promoter occupancy in a HeLa clone cell line [MBD2 knockdown (KD) HeLa cells] constitutively depleted in MBD2 by a transgene expressing a siRNA targeting the mRNA coding for this protein (26) .
Quantitative competitive RT-PCR assays indicated that 89-96% MBD2 mRNA depletion was obtained and maintained over many passages in MBD2 KD HeLa cells. This low level of MBD2 transcripts was correlated with a very low level of MBD2 protein, which was almost undetectable in western blot experiments (26) . In addition, neither the amounts of MeCP2 and MBD1 transcripts nor the amounts of the corresponding proteins were altered by MBD2 depletion (data not shown).
As MBD2 belongs to the DNA methylation machinery, a prolonged MBD2 depletion might alter DNA methylation patterns. Therefore, the DNA methylation patterns of the hTERT promoter were determined in MBD2 KD HeLa cells. DNA extracted from the cell lines was modified and amplified by PCR with primers specifically designed to amplify bisulfite-modified DNA sequence of the hTERT promoter and proximal exonic region. PCR fragments were cloned and sequenced. The analysis of 10 clones from wild-type HeLa cells and MBD2 KD HeLa cells indicated that over the hypermethylated hTERT promoter and proximal exonic region, a small sequence (positions nt À165 to nt À80), corresponding to a part of the hTERT core promoter, was hypomethylated in the two cell lines analyzed ( Figure 1B) . Indeed, this region exhibit a low level of methylation ($30%) but no significant difference was observed between wild-type HeLa cells and HeLa cells depleted in MBD2. Thus, the methylation patterns of the hTERT promoter in MBD2 KD HeLa cells were not altered by the absence of MBD2.
As expected, in HeLa cells depleted in MBD2 proteins, ChIP assays indicated that MBD2 was no longer detected at the hypermethylated region of the hTERT core promoter ( Figure 1C ). Furthermore, this region seemed to remain free of MBD proteins since the immunoprecipitated fractions are depleted in the methylated hTERT promoter when anti-MeCP2 or anti-MBD1 antibodies were used in ChIP experiments ( Figure 1C) .
Thus, the hypermethylated region of the hTERT promoter is specifically targeted by MBD2 in HeLa cells and no redundancy between MBD2 and MeCP2 or MBD1 was observed at this hypermethylated region.
MBD2 depletion enhances hTERT gene transcription in HeLa cells
MBD2 is a member of the MBD protein family and their methylationdependent repressive activities are now well established (29) . Therefore, we investigated the potential involvement of MBD2 in the repression of the endogenous hTERT promoter in HeLa cells.
First, we determined the consequence of a transient MBD2 depletion on the expression of hTERT in HeLa cells. At 24 h intervals after MBD2-specific siRNA transfection, RNA was extracted and the levels of hTERT and MBD2 transcripts determined by RT-PCR assays were compared with their levels in HeLa cells transfected with a non-specific siRNA. Quantitative competitive RT-PCR assays (27) indicated that a reduction of $90% in MBD2 mRNA level was reached 24 h after transfection with MBD2 siRNA and maintained .96 h after transfection ( Figure 3A) . Western blot analysis also showed a dramatic decrease in MBD2 proteins in these cells (data not shown). In HeLa cells, 48 h after the MBD2 siRNA transfection, an elevation of 1.2-fold of hTERT mRNA level was observed when compared with HeLa cells transfected with a non-specific siRNA. This stimulation increased to a maximum of 1.9 at 96 h after MBD2 siRNA treatment. The expression level of hTERT was determined using relative RT-PCR ( Figure  3A ) and identical results were obtained with real-time RT-PCR for critical points ( Figure 3B ). It should be noted that neither the level of MBD2 transcripts nor the level of hTERT transcripts were altered by non-specific siRNA transfection when compared with untreated wildtype HeLa cells (data not shown).
These data suggest that MBD2 actually represses hTERT expression in HeLa cells.
Stimulation of hTERT transcription in MBD2 KD HeLa cells is reversed by ectopic expression of Mbd2
The MBD2 KD HeLa cell line offers the opportunity to investigate the functional control of the specific repression of hTERT by MBD2. In this cell line, MBD2 expression can be rescued using pRev-Mbd2, a vector coding for a mouse Mbd2 RNA containing five silent point mutations and, therefore, refractory to siRNA-mediated decay (26) . We also observed a 2-fold stimulation of hTERT expression in the MBD2 KD HeLa cells as compared with wild-type HeLa cells (Figure 4) . In these Our results demonstrate that MBD2 specifically binds to hTERT and represses its expression in HeLa cells.
MBD2 hTERT repression is specifically observed in hTERTmethylated telomerase-positive cancer cell lines and independent of the cellular types Data obtained suggest that MBD2 might be a general repressor of hTERT transcription in hTERT-methylated telomerase-positive cells. In order to address this point, we tested whether the above-mentioned MBD2 KD-mediated hTERT stimulation in HeLa cells could be recapitulated in other hTERT-methylated cell lines. A functional study was undertaken in different cell lines exhibiting characteristic hTERT DNA methylation patterns: (i) MCF-7, LAN-1 and HepG2 cells, three telomerase-positive cancer cell lines showing an hTERT core promoter unmethylated or slightly methylated despite an hypermethylated CpG island (ii) NCCIT cells, an hTERT-unmethylated telomerase-positive teratocarcinoma cell line and (iii) MRC5 cells, an hTERT-unmethylated telomerase-negative normal embryonic cell line. The hTERT core promoter methylation status of these cell lines and the corresponding transcript levels are shown in Figure 5 . Control experiments indicated that these cell lines exhibited approximatively the same level of MBD2 transcripts (4.8 ± 2.7 Â 10 6 mRNA molecules per microgram of total RNA), with the exception of NCCIT (7 Â 10 4 mRNA molecules per microgram of total RNA).
As observed in HeLa cells, a significant decrease of MBD2 transcripts (60-79%) was observed in the different cell lines 96 h after MBD2 siRNA transfection. Relative to the transfection with a nonspecific siRNA, a $2-fold increase in hTERT mRNA was observed in all hTERT-methylated cell lines, LAN-1, MCF7 and HepG2 cells. In contrast, MBD2 depletion did not affect hTERT expression in hTERTunmethylated cell lines, NCCIT and MRC5 cells (Figure 6 ). Since MBD2 does no bind to unmethylated DNA (24, 25) , these data indicate that hTERT induction due to MBD2 depletion is not mediated by an indirect effect.
Taken together, the specific transcriptional repression of hTERT by MBD2 does not seem to be restricted to a particular cancer cell line since this effect was observed in cervix, breast, liver and neuroblastoma cancer cell lines. Thus, MBD2 seems to be a general repressor of hTERT in hTERT-methylated telomerase-positive cells.
Discussion
Most ($96%) of the CpG islands are unmethylated in normal cells (30) , whereas hypermethylation of these sequences is a characteristic MBD2 is a selective repressor of hTERT of cancer cells (1) . These aberrant DNA methylation patterns have been correlated with the transcriptional silencing of genes undergoing such alterations at their 5# end CpG islands. The hTERT gene has provided an interesting exception since a bimodal alteration of the DNA methylation status of its 5# end CpG island is associated with its expression in $85% of cancer cells and tumors tissues (4, 5) . The large CpG island, 2.6 kb in length, lying from nt À1102 to nt þ1519 from the hTERT transcription, is hypermethylated at the exception of a short region (positions nt À165 to nt À80) that is unmethylated or slightly methylated despite highly methylated border regions (16, 17) . This particular pattern of methylation seems crucial for establishing The relative level of each mRNA was calculated on the basis of the two standard curves using the relative quantification method. At least three independent determinations of fold differences were used to calculate the average fold difference values and associated standard deviation (P 5 0.0027; t-test). hTERT expression at a basal level. Indeed, hypermethylation of CpG islands seems to be a crucial event in carcinogenesis. Thus, the methylation-free region in hTERT promoter may result from antagonistic pressure between the mechanisms leading to aberrant methylation and the need to keep hTERT expressed for unlimited life span of cancer cells.
A body of evidence has been accumulated concerning association between hypermethylation of CpG islands, transcriptional silencing and MBD-proteins binding (21) . ChIP experiments and ChIP-on-chip analysis indicate that MBD2 associated the hypermethylated CpG island of hTERT. In this context, MBD2 seems to be a limiting factor rather than a transcriptional silencer.
Recently, a large screening of tumor suppressor gene promoters in 10 cell lines showed that human cancer cell lines tend to use a particular MBD protein (31) . Furthermore, in MRC5 cells, ChIP experiments have indicated that MeCP2 and MBD2 proteins have nonoverlapping binding specificities in vivo (23) . These data, as well as our data are in favor of the 'one gene-one MBD' hypothesis, at least for some genes. Indeed, MBD2 was specifically associated with the methylated region of the hTERT CpG island, whereas MeCP2 and MBD1 were not detected at this locus. Moreover, MBD2 depletion did not induce MeCP2 or MBD1 binding at this methylated area in HeLa cells. Thus, the specificity of MBD proteins does not seem to be driven by their relative concentrations in a cell line, as it was suggested in an other study (31) : a strong expression of a particular MBD is not necessarily associated with its preferential use in promoters.
Several studies have shown that transcriptional activation could be realized upon depletion of MBD proteins by RNA interference (RNAi) (26, 28) . A large-scale microarray analysis indicated that 15% of 6386 genes analyzed exhibit an increased expression change between untreated and triple MBD-depleted cells (28) . It should be noted that for single-MBD interference, MBD2 depletion was the protein most commonly involved in the observed release of gene silencing by far (28) . These data suggest that MBD2 plays an important role in methylation-dependent gene silencing. MBD2 depletion mediated by RNAi stimulates hTERT expression, either in stable KD HeLa clones or in transiently transfected HeLa cells. A 2-fold stimulation of hTERT expression upon MBD2 depletion was observed, suggesting that MBD2 plays an important role in the regulation of this gene. Indeed, in human cell lines, fold changes induced by MBD2 depletion is also of the same range, 2-fold for NBR2 induced by MBD2 siRNA (26) and microarray analysis of MBD2-depleted cells exhibited a mean fold change of 7 (28) . Furthermore, the fold change observed in Mbd2-deficient mouse cells is not very different from our own data. For example, it has been shown (32) that Mbd2À/À fibroblasts had 3-fold higher levels of Xist than wild-type cells. Moreover, elevated hTERT transcription upon MBD2 depletion is not limited to cervix (HeLa cells) since this effect was observed in breast, liver and neuroblastoma cancer cell lines. MBD2 RNAi experiments in cell lines exhibiting unmethylated hTERT CpG island (MRC5 and NCCIT) did not affect hTERT transcription indicating that MBD2 specifically and directly represses hTERT expression in methylationdependent manner. Collectively, these data strongly suggest that MBD2 is a general repressor of hTERT expression in cancer cells.
A considerable number of transcription factors have been proposed as negative regulators of hTERT transcription. Nevertheless, direct evidence indicating that hTERT gene transcription is downregulated remains to be firmly established. Thus, MBD2 may represent a new factor directly involved in the negative regulation of hTERT expression. In cancer cells, MBD2 seems to play a specific role since its binding to the hypermethylated part of the hTERT promoter establishes a direct link between a common DNA alteration of tumor cells, CpG hypermethylation and a reduced level of hTERT transcription. The binding of MBD2 represents an additional layer for the control of hTERT expression, thereby underlying the importance of hTERT regulation in immortalized and cancers cells.
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